Epsilon Healthcare posts record quarter as manufacturing arm powers growth

An announcement from Epsilon Healthcare Limited ( (AU:EPN) ) is now available.

Epsilon Healthcare reported record quarterly customer receipts of $3.14 million for the March 2026 quarter, a 154% year-on-year increase, with group revenue reaching $3.29 million and a revenue run-rate of about $1.1 million per month. Management said the performance reflects strong execution of its integrated healthcare strategy, rising demand across clinical, manufacturing and pharmacy divisions, and positions the group to accelerate expansion and build operating leverage as it pursues a larger role as a globally competitive healthcare and manufacturing partner.

The company’s Epsilon Pharma contract development and manufacturing business led growth with a 149% year-on-year increase, supported by expanded product and service offerings, higher GMP manufacturing volumes and a growing pipeline of domestic and international contracts. With Epsilon Pharmacy now generating an annualised $2.3 million in revenue and international opportunities increasing on the back of dual domestic and European GMP licences, Epsilon is seeking to scale operations further and capture a larger share of global demand for natural medicines and APIs.

More about Epsilon Healthcare Limited

Epsilon Healthcare Limited is an Australian diversified healthcare company focused on contract development and manufacturing, clinical services and pharmacy operations. Through its Epsilon Pharma CDMO unit and Epsilon Clinics and Pharmacy businesses, the company targets both domestic and international markets for natural medicines and active pharmaceutical ingredients, leveraging Australian and European GMP certifications.

YTD Price Performance: -39.39%

Average Trading Volume: 187,892

Technical Sentiment Signal: Sell

Current Market Cap: A$7.78M

For detailed information about EPN stock, go to TipRanks’ Stock Analysis page.